Megan Li Xian Lee

Megan Li Xian Lee

Auto-generated profile, based on publicly available information

Megan Li Xian Lee

Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2025 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
MLMegan Li Xian Lee
Megan Li Xian Lee
KNKim Ngan T. Nguyen
Kim Ngan T. Nguyen
WPWei Wei Pang
Wei Wei Pang
Federico TortaFederico Torta
Federico Torta
YCYap Seng Chong
Yap Seng Chong
AGAmaury Cazenave Gassiot
Amaury Cazenave Gassiot

8 June 2026 in Biochemical Society Transactions
Verified
Journal Article
Open access
MLMegan Li Xian Lee
Megan Li Xian Lee
UEUntzizu Elejalde
Untzizu Elejalde
AGAmaury Cazenave Gassiot
Amaury Cazenave Gassiot
As the optimal source of nutrition for infants, investigations into the human milk lipidome have been quite extensive. Much of the work, however, has been focused on major lipid components such as triglycerides, possibly undermining its actual complexity. This review focuses on two minor but bioactive lipid classes in human milk: fatty acid esters of hydroxy fatty acids (FAHFAs) and alkyl-diacylglycerols (TG(O)s). FAHFAs are known to exhibit anti-diabetic and anti-inflammatory effects, while TG(O)s are important for the prevention of childhood obesity. With the knowledge that early nutrition and metabolic health influence the risk of metabolic dysfunctions later in life, a comprehensive understanding of FAHFAs and TG(O)s, along with reliable characterisations in human milk, would better allow for the development of accurate human milk fat substitutes. This could have future implications as alternative or preventive treatments for infants with early markers of metabolic dysfunction, including diabetes and obesity. The structural characteristics, pathways for biosynthesis and degradation, bioactivity, dietary sources, and characterisations of FAHFAs and TG(O)s in human milk are discussed. Their statuses as emerging lipid classes, however, is reflected in the incomplete understanding of their biochemical pathways. Characterisations of FAHFAs and TG(O)s in human milk are relatively poor, and contradicting results are reported. This review also addresses the challenges involved in the study of minor lipids in complex biological matrices, and the possible reasons underlying the slower evolution of our understanding of FAHFAs and TG(O)s in human milk and their associations with health outcomes.